Atypical hemolytic uremic syndrome: a nationwide Colombian pediatric series
datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
dc.contributor.author | Espitaleta, Zilac | |
dc.contributor.author | Domínguez-Vargas, Alex | |
dc.contributor.author | Villamizar-Martínez, Johanna | |
dc.contributor.author | Carrascal-Guzmán, Martha | |
dc.contributor.author | Guerrero-Tinoco, Gustavo | |
dc.contributor.author | Silva-Diaz, Diana | |
dc.contributor.author | Baquero, Richard | |
dc.contributor.author | Pinto-Bernal, Claudia | |
dc.contributor.author | González-Chaparro, Luz | |
dc.contributor.author | Rojas-Rosas, Luisa | |
dc.contributor.author | Amado-Niño, Pilar | |
dc.contributor.author | Castillo-Arteaga, Mariángel | |
dc.contributor.author | Alvarez-Gomez, Yeferson | |
dc.contributor.author | Arguello-Muñoz, Laura | |
dc.contributor.author | Morales-Camacho, William | |
dc.contributor.author | León-Guerra, Oscar | |
dc.contributor.author | Egea, Eduardo | |
dc.contributor.author | Galeano-Rodríguez, Ricardo | |
dc.contributor.author | Quintero-Gómez, Ana | |
dc.contributor.author | Aroca-Martínez, Gustavo | |
dc.contributor.author | G. Musso, Carlos | |
dc.date.accessioned | 2023-04-17T15:05:02Z | |
dc.date.available | 2023-04-17T15:05:02Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Background Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated kidney disease with genetic predisposition and represents up to 10% of pediatric hemolytic uremic syndrome (HUS) cases. Few studies have evaluated aHUS in Latin American population. We studied a Colombian pediatric cohort to delineate disease presentation and outcomes. Methods A multicenter cohort of 27 Colombian children with aHUS were enrolled between 2010 to 2019. Patients were grouped by age at onset. Clinical features were compared using analysis of variance (ANOVA) and Fisher exact tests. Renal biopsy was performed on six patients who were suspected of having other renal diseases before aHUS diagnosis. Results Most patients were male (70%). The onset of aHUS occurred frequently before age 4 years (60%) and followed gastroenteritis as the main triggering event (52%). Age groups were comparable in clinical presentation, disease severity, treatment, and outcomes. Pulmonary involvement (67%) was the main extrarenal manifestation. A higher frequency was observed in the 1–7 age group (p = 0.01). Renal biopsies were as follows: three had membranoproliferative glomerulonephritis (MPGN) type I, one MPGN type III, one C3-glomerulonephritis, and one rapidly progressive glomerulonephritis. Genetic screening was available in five patients and identified 2xCFHR5, 2xMCP, and 1xADAMTS-13/THBD mutations. A total of 15 relapses were seen, of which 8 (72%) occurred in the 1–7 age group. The renal outcome was not significantly different regardless of age group. Conclusion In our cohort, we observed a relatively high frequency of extrarenal involvement at first presentation represented by pulmonary manifestations. The renal prognosis at initial presentation was worse than in previous reports. | eng |
dc.format.mimetype | spa | |
dc.identifier.doi | https://doi.org/10.21203/rs.3.rs-2670677/v1 | eng |
dc.identifier.issn | 26935015 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12442/12236 | |
dc.identifier.url | https://assets.researchsquare.com/files/rs-2670677/v1/dfbb9c86-25d8-44c0-99f6-db8a73a8af70.pdf?c=1681156974 | eng |
dc.language.iso | eng | eng |
dc.publisher | Research Square Company | eng |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Research square | eng |
dc.source | Vol XX, No X, (2023) | |
dc.subject | Pediatric Atypical hemolytic uremic syndrome | eng |
dc.subject | Thrombotic microangiopathy | eng |
dc.subject | Extrarenal manifestations | eng |
dc.title | Atypical hemolytic uremic syndrome: a nationwide Colombian pediatric series | eng |
dc.type.driver | info:eu-repo/semantics/article | eng |
dc.type.spa | Artículo científico | spa |
dcterms.references | Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens. 2010;19(4):372-378. doi:10.1097/MNH.0b013e32833aff4a | eng |
dcterms.references | Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687. doi:10.1056/NEJMra0902814 | eng |
dcterms.references | Kurosawa S, Stearns-Kurosawa DJ. Complement, thrombotic microangiopathy, and disseminated intravascular coagulation. J intensive care. 2014;2(1):65. doi:10.1186/s40560-014-0061-4 | eng |
dcterms.references | Raina R, Krishnappa V, Blaha T, et al. file:///C:/Users/Alex Dominguez/Desktop/raina2018.pdf. Ther Apher Dial. 2019;23(1):4-21. doi:10.1111/1744-9987.12763 | eng |
dcterms.references | Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi:10.2215/CJN.02210310 | eng |
dcterms.references | Dragon-Durey M-A, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with the atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555-563. doi:10.1681/ASN.2004050380 | eng |
dcterms.references | Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55-64. doi:10.1681/ASN.2013050453 | eng |
dcterms.references | Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279. doi:10.1182/blood-2005-10- 007252 | eng |
dcterms.references | Raina R, Krishnappa V, Blaha T, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019;23(1):4-21. doi:10.1111/1744-9987.12763 | eng |
dcterms.references | Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol. 2001;12(2):297-307. doi:10.1681/ASN.V122297 | eng |
dcterms.references | Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide french series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215/CJN.04760512 | eng |
dcterms.references | Kavanagh D, Richards A, Noris M, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol. 2008;45(1):95-105. doi:10.1016/j.molimm.2007.05.004 | eng |
dcterms.references | Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104(1):240-245. doi:10.1073/pnas.0603420103 | eng |
dcterms.references | Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112(13):4948-4952. doi:10.1182/blood-2008-01-133702 | eng |
dcterms.references | Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome. N Engl J Med. 2009;361(4):345-357. doi:10.1056/NEJMoa0810739 | eng |
dcterms.references | Mills MC, Rahal C. A scientometric review of genome-wide association studies. Commun Biol. 2019;2(1):9. doi:10.1038/s42003-018-0261-x | eng |
dcterms.references | Jiménez-Kaufmann A, Chong AY, Cortés A, et al. Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. Front Genet. 2022;12(January):1-11. doi:10.3389/fgene.2021.719791 | eng |
dcterms.references | Homburger JR, Moreno-Estrada A, Gignoux CR, et al. Genomic Insights into the Ancestry and Demographic History of South America. PLoS Genet. 2015;11(12):1-26. doi:10.1371/journal.pgen.1005602 | eng |
dcterms.references | Conley AB, Rishishwar L, Norris ET, et al. A comparative analysis of genetic ancestry and admixture in the Colombian populations of chocó and Medellín. G3 Genes, Genomes, Genet. 2017;7(10):3435-3447. doi:10.1534/g3.117.1118 | eng |
dcterms.references | Geerdink LM, Westra D, Van Wijk JAE, et al. Atypical hemolytic uremic syndrome in children: Complement mutations and clinical characteristics. Pediatr Nephrol. 2012;27(8):1283-1291. doi:10.1007/s00467-012-2131-y | eng |
dcterms.references | Pablo Córdoba J, Mariel Contreras K, Larrarte C, et al. Síndrome hemolítico urémico atípico, revisión de la literatura y documento de consenso. Enfoque diagnóstico y tratamiento. Rev Colomb Nefrol. 2015;2(1):19-40. | spa |
dcterms.references | Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Reports. 2019;4(11):1568-1576. doi:10.1016/j.ekir.2019.07.016 | eng |
dcterms.references | Brodsky RA. Eculizumab and aHUS: to stop or not. Blood. 2021;137(18):2419-2420. doi:10.1182/blood.2020010234 | eng |
dcterms.references | R Core Team. R: A Language and Environment for Statistical Computing. Published online 2015. | eng |
dcterms.references | Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide french series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215/CJN.04760512 | eng |
dcterms.references | Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7(5):e1002079. doi:10.1371/journal.pgen.1002079 | eng |
dcterms.references | Manenti L, Gnappi E, Vaglio A, et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant. 2013;28(9):2246-2259. doi:10.1093/ndt/gft220 | eng |
dcterms.references | Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34(8):1337-1348. doi:10.1007/s00467-018-4039-7 | eng |
dcterms.references | Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408-418. doi:10.1016/j.kint.2018.02.029 | eng |
dcterms.references | Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. doi:10.3389/fped.2014.00097 | eng |
dcterms.references | Cabarcas-Barbosa O, Aroca-Martínez G, Musso CG, et al. Atypical hemolytic uremic syndrome in the Colombian Caribbean: its particular characteristics. Int Urol Nephrol. 2022;54(6):1323-1330. doi:10.1007/s11255-021-03011- 5 | eng |
dcterms.references | Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34(8):1337-1348. doi:10.1007/s00467-018-4039-7 | eng |
dcterms.references | Brackman D, Sartz L, Leh S, et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant. 2011;26(10):3399-3403. doi:10.1093/ndt/gfr422 | eng |
dcterms.references | Siegler RL, Brewer ED, Pysher TJ. Hemolytic uremic syndrome associated with glomerular disease. Am J Kidney Dis. 1989;13(2):144-147. doi:10.1016/s0272-6386(89)80133-7 | eng |
dcterms.references | Dische FE, Culliford EJ, Parsons V. Haemolytic uraemic syndrome and idiopathic membranous glomerulonephritis. Br Med J. 1978;1(6120):1112-1113. doi:10.1136/bmj.1.6120.1112 | eng |
dcterms.references | Jha V, Murthy MSN, Kohli HS, et al. Secondary Membranoproliferative Glomerulonephritis Due to Hemolytic Uremic Syndrome: An Unusual Presentation. Ren Fail. 1998;20(6):845-850. doi:10.3109/08860229809045182 | eng |
dcterms.references | Licht C, Fremeaux-Bacchi V. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost. 2009;101(02):271-278. doi:10.1160/TH08-09-0575 | eng |
dcterms.references | Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulonephritis. Nephrol Dial Transplant. 2016;31(5):717-725. doi:10.1093/ndt/gfu317 | eng |
dcterms.references | Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulonephritis. Pediatr Nephrol. Published online 2018:1- 13. doi:10.1007/s00467-018-3989-0 | eng |
dcterms.references | Józsi M, Barlow PN, Meri S. Editorial: Function and Dysfunction of Complement Factor H. Front Immunol. 2022;12. doi:10.3389/fimmu.2021.831044 | eng |
dcterms.references | Zhang Y, Ghiringhelli Borsa N, Shao D, et al. Factor H Autoantibodies and Complement-Mediated Diseases. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.607211 | eng |
dcterms.references | Gatault P, Brachet G, Ternant D, et al. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs. 2015;7(6):1205-1211. doi:10.1080/19420862.2015.1086049 | eng |
dcterms.references | Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701-711. doi:10.1016/j.kint.2015.11.026 | eng |
oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Atypical_hemolytic_uremic_syndrome.pdf
- Tamaño:
- 5.18 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 381 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: